Sickle Cell Disease, a genetic blood disorder, causes severe health complications such as anemia, frequent pain episodes, and other debilitating symptoms. The condition affects millions globally, with a notable prevalence in India and Africa. According to the 2011 Census, 8.6% of India's population is from tribal communities, many of whom are disproportionately impacted by SCD. Traditionally, Hydroxyurea solutions require refrigeration between 2–8°C, presenting challenges for distribution in remote areas with limited cold storage facilities.

Akums' new oral suspension, which remains stable at room temperature, offers a crucial advantage in overcoming these challenges. By eliminating the need for refrigeration, the formulation ensures broader distribution and accessibility, especially in underserved tribal regions.

Sanjeev Jain, Managing Director of Akums, expressed pride in this achievement, stating, "We are honored to receive this patent for a formulation that has the potential to significantly improve the lives of SCD patients in India and Africa. At Akums, our focus is on delivering innovative healthcare solutions that tackle real-world challenges and enhance patient outcomes. Our commitment is to provide affordable medicines for Orphan Drugs, reducing dependency on imports and ensuring timely treatment for rare diseases."

Sandeep Jain, also Managing Director of Akums, emphasized the alignment with the 'Make in India' initiative and the company's dedication to offering high-quality, cost-effective pharmaceutical solutions. He noted, "This patent underscores our commitment to innovation and affordability, reflecting the vision of the Government of India. With 67.8 million tribal community members across various states in India, many of whom suffer from SCD, our new formulation provides a much-needed solution, particularly for pediatric and adolescent patients. The stability of our oral suspension at room temperature ensures greater accessibility and efficient distribution."

The new Hydroxyurea suspension aligns with India's National Sickle Cell Anemia Mission, led by Prime Minister Narendra Modi, which aims to enhance the quality of life for SCD patients through improved treatment options. Unlike the traditional Hydroxyurea capsule (500mg), the new suspension offers dose flexibility based on patient body weight, providing a significant advantage for younger patients.

With this patent, Akums Drugs not only continues to advance healthcare through innovation but also upholds its commitment to delivering affordable, high-quality medicines, making life-saving treatments more accessible to those in need.